Investigational drug · Phase 2
OMT-28
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Primary Mitochondrial Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Jan 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
3
Any phase or sponsor naming "OMT-28"
First trial start
2023
May 22, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "OMT-28", any sponsor or status.
Conditions studied
As listed on its trial records.
- Primary Mitochondrial Disease
Largest trials
Live from ClinicalTrials.gov: studies naming "OMT-28" as an intervention, largest first.
- Study on OMT-28 in Maintenance of Sinus Rhythm in Patients With Persistent Atrial Fibrillation (AF)Pivotal-lookingCompleted
Omeicos Therapeutics GmbHIndustry
NCT03906799 · 136 participants · Start Mar 19, 2019 · Primary completion Nov 20, 2019
Drug: OMT-28; Placebo · For: Atrial Fibrillation
Sites: Sofia, Bulgaria; Stara Zagora, Bulgaria; Varna, Bulgaria · 25 sites in all
Omeicos Therapeutics GmbHIndustry
NCT03078738 · 75 participants · Start Feb 8, 2017 · Primary completion Mar 12, 2018
Drug: OMT-28 · For: Healthy Volunteers
Sites: Mönchengladbach, Germany
Omeicos Therapeutics GmbHIndustry
NCT05972954 · 28 participants · Start May 22, 2023 · Primary completion May 14, 2025
Drug: OMT-28 · For: Primary Mitochondrial Disease
Sites: Bonn, Germany; Halle, Germany; Munich, Germany · 9 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- OMT-28, a synthetic analog of 17,18-epoxyeicosatetraenoic acid, mitigates lipopolysaccharide-induced lung injury in mice.
Tsubouchi H, Inomata R, Yanagi S, et al. · Eur J Pharmacol 2025
- Cardioprotective properties of OMT-28, a synthetic analog of omega-3 epoxyeicosanoids.
Kranrod J, Konkel A, Valencia R, et al. · J Biol Chem 2024
- [A survey of parents' cognition about orofacial myofunctional therapy in children with orofacial muscle dysfunction].
Ding Q, Wang S, Lai GY · Shanghai Kou Qiang Yi Xue 2021
- Assessment of OMT-28, a synthetic analog of omega-3 epoxyeicosanoids, in patients with persistent atrial fibrillation: Rationale and design of the PROMISE-AF phase II study.
Berlin S, Goette A, Summo L, et al. · Int J Cardiol Heart Vasc 2020
Also in development for Primary Mitochondrial Disease
- KL1333NapazimonePhase 22 trials
Pharming Technologies B.V. · Primary Mitochondrial Disease, Mitochondrial Diseases
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.